Tweet
This study is a bit dated, but still applicable, as it used BEAM chemotherapy and covered a range of types of MS, including many with lower EDSS scores. It would be interesting to see longer-term results now that it is 2012. - Dave
Autologous hematopoietic stem cell transplantation in multiple sclerosis
Yury L. Shevchenko1, Andrei A. Novik1, Alexey N. Kuznetsov1, Boris V. Afanasyev2, Igor A. Lisukov3, Oleg A. Rykavicin4, Аlexandr A. Myasnikov5, Vladimir Y. Melnichenko1, Denis A. Fedorenko1, Tatyana I. Ionova6, Roman A. Ivanov1, and Gary Gorodokin7 on behalf of the Russian Cooperative Group for Cellular Therapy
1Pirogov National Medical Surgical Center, Moscow, Russia; 2Pavlov State Medical University, St. Petersburg, Russia; 3Institute of Clinical Immunology, Siberian Branch of Russian Academy of Science, Novosibirsk, Russia; 4Burdenko Central Military Hospital, Moscow, Russia; 5Republic Hospital, Petrozavodsk, Russia; 6Multinational Center of Quality of Life Research, St. Petersburg, Russia; 7New Jersey Center for Quality of Life and Health Outcome Research, NJ, USA
Correspondence: Andrei A Novik, Department of Haematology and Cellular Therapy, Pirogov National Medical Surgical Center, 70 Nizhnaya Pervomaiskaya str., 105 207 Moscow, Russia
Summary
Background: Although there is no effective cure for this disease, high-dose chemotherapy (HDCT), together with autologous hematopoietic stem cell transplantation (auto-HSCT) offers promising results in the treatment of multiple sclerosis (MS) patients.
Methods: In this paper we present results of a prospective clinical study of safety and efficacy of HDCT+auto-HSCT in MS patients. One hundred and nine patients with various types of MS were included in this study. The patients underwent early, conventional, or salvage/late transplantation.
Results: The transplantation procedure was well tolerated by MS patients, with no transplant-related deaths at all. The efficacy analysis was performed in 79 patients. Forty-two achieved an objective improvement of neurological symptoms (defined as a ≥0.5 point decrease in EDSS score as compared to the baseline and confirmed over 6 months), and 37 patients had disease stabilization (steady EDSS level as compared to the baseline and confirmed over 6 months). Quality of life (QoL) was assessed in 44 patients. Thirty-nine patients exhibited a QoL response 1 year after transplantation.
Conclusions: This study provides ample evidence in support of HDCT+auto-HSCT efficacy in MS patients. The results obtained show that transplantation appears to be effective in patients with various types of MS.
Full Study:
http://www.ctt-journal.com/index.php?id=164....i
Autologous hematopoietic stem cell transplantation in multiple sclerosis
Yury L. Shevchenko1, Andrei A. Novik1, Alexey N. Kuznetsov1, Boris V. Afanasyev2, Igor A. Lisukov3, Oleg A. Rykavicin4, Аlexandr A. Myasnikov5, Vladimir Y. Melnichenko1, Denis A. Fedorenko1, Tatyana I. Ionova6, Roman A. Ivanov1, and Gary Gorodokin7 on behalf of the Russian Cooperative Group for Cellular Therapy
1Pirogov National Medical Surgical Center, Moscow, Russia; 2Pavlov State Medical University, St. Petersburg, Russia; 3Institute of Clinical Immunology, Siberian Branch of Russian Academy of Science, Novosibirsk, Russia; 4Burdenko Central Military Hospital, Moscow, Russia; 5Republic Hospital, Petrozavodsk, Russia; 6Multinational Center of Quality of Life Research, St. Petersburg, Russia; 7New Jersey Center for Quality of Life and Health Outcome Research, NJ, USA
Correspondence: Andrei A Novik, Department of Haematology and Cellular Therapy, Pirogov National Medical Surgical Center, 70 Nizhnaya Pervomaiskaya str., 105 207 Moscow, Russia
Summary
Background: Although there is no effective cure for this disease, high-dose chemotherapy (HDCT), together with autologous hematopoietic stem cell transplantation (auto-HSCT) offers promising results in the treatment of multiple sclerosis (MS) patients.
Methods: In this paper we present results of a prospective clinical study of safety and efficacy of HDCT+auto-HSCT in MS patients. One hundred and nine patients with various types of MS were included in this study. The patients underwent early, conventional, or salvage/late transplantation.
Results: The transplantation procedure was well tolerated by MS patients, with no transplant-related deaths at all. The efficacy analysis was performed in 79 patients. Forty-two achieved an objective improvement of neurological symptoms (defined as a ≥0.5 point decrease in EDSS score as compared to the baseline and confirmed over 6 months), and 37 patients had disease stabilization (steady EDSS level as compared to the baseline and confirmed over 6 months). Quality of life (QoL) was assessed in 44 patients. Thirty-nine patients exhibited a QoL response 1 year after transplantation.
Conclusions: This study provides ample evidence in support of HDCT+auto-HSCT efficacy in MS patients. The results obtained show that transplantation appears to be effective in patients with various types of MS.
Full Study:
http://www.ctt-journal.com/index.php?id=164....i